Inhibin-A and inhibin-B in cyclic and pregnant mares, and mares with granulosa-theca cell tumors: Physiological and diagnostic implications

A.J. Conley a,*, E.L. Scholtz a, G. Dujovne a, R.F. Cotterman a, E.L. Legacki a, R.C. Uliani b, M.A. Alvarenga b, B.A. Ball c, B. Kalra d, G.V. Savjani d, A. Kumar d
a Department of Population Health & Reproduction, School of Veterinary Medicine, University of California, Davis, CA, 95616, USA
b Department of Animal Reproduction and Veterinary Radiology, Sao Paulo State University, UNESP, Botucatu, Brazil
c Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington KY, USA
d Ansh Labs LLC, Webster, TX, USA

ARTICLE INFO

Article history:
Received 22 September 2017
Received in revised form 29 November 2017
Accepted 1 December 2017
Available online 7 December 2017

Keywords:
Inhibin-A
Inhibin-B
Equine
Cyclic
Ovarian tumor

ABSTRACT

Studies in mares have examined serum inhibin concentrations using immuno-assays unable to distinguish dimeric inhibin-A from inhibin-B isoforms. Inhibin-A and inhibin-B immuno-assays were used to investigate concentrations in cyclic mares, young and old (6 vs 19 years old, respectively) mares following hemi-ovariectomy, mares during pregnancy and in mares with confirmed granulosa cell tumors (GCTs). Mares with inter-ovulatory intervals of 26 days had ovulatory peaks of inhibin-A averaging 80 pg/mL with a mid-cycle nadir of 5 pg/mL. Inhibin-A and inhibin-B concentrations were highly correlated (r = +0.79, P < 0.01) though peak and nadir concentrations of inhibin-B were not significantly different. However, the ratio of inhibin-A to inhibin-B (A/B) changed significantly through the cycle, highest at ovulation and <1 (more inhibin-B than inhibin-A) at mid-cycle. Two mares with grossly extended inter-ovulatory intervals demonstrated mid-cycle inhibin-A (and inhibin-B) excursions suggestive of follicular waves. Follicle-stimulating hormone was negatively correlated with inhibin-A and inhibin-B concentrations in all 6 mares. Hemi-ovariectomy in young mares resulted in a significant decrease in inhibin-A and inhibin-B concentrations one day later (P < 0.05) but older mares did not, suggesting a possible extra-ovarian source(s) of these hormones. Both inhibin isoforms dropped to very low levels during pregnancy (P < 0.0001), inhibin-A (P < 0.0001) more rapidly than inhibin-B (P < 0.05), so that inhibin-B became the predominant measured form throughout most of gestation (P < 0.05). Mares with confirmed GCTs had elevated inhibin-B concentrations more reliably than inhibin-A but neither inhibin-A nor inhibin-B was correlated with anti-Müllerian hormone concentrations. Collectively, concentrations of inhibin-A and inhibin-B were aligned with physiological events in healthy mares, though more pronounced cyclic changes were seen with inhibin-A. Inhibin-B concentrations were significantly associated with GCTs (P < 0.01), inhibin-A concentrations were not. While both inhibin-A and inhibin-B concentrations track physiological events such as cyclic follicular activity, only inhibin-B concentrations effectively signal ovarian neoplasia in mares.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

The inhibins are principally gonadal hormones that influence reproductive function by feedback at the level of pituitary where they regulate follicle stimulating hormone (FSH) secretion [1,2]. As a consequence, the measurement of inhibins has long been useful in the assessment of reproductive function in women [2], as well as in the diagnosis of ovarian cancers particularly granulosa cell tumors and mucinous carcinomas [3]. Similarly, inhibins have proven to be a useful marker for ovarian function in cyclic mares [4] even if more limited in utility in other livestock species [5]. Until recently, inhibins have been the main, and most valuable, endocrine marker for ovarian granulosa-theca cell tumors (GCTs) in mares, one of the most common of all equine tumors [6]. The inhibins are dimeric glycoproteins comprised of a common α-subunit linked to either of two β-subunits (βA or βB) that give rise to the two major, biologically active forms, inhibin-A and inhibin-B, respectively. This

* Corresponding author.
E-mail address: ajconley@ucdavis.edu (A.J. Conley).

https://doi.org/10.1016/j.theriogenology.2017.12.003
0093-691X/© 2017 Elsevier Inc. All rights reserved.
involves expression of prepro-forms of the protein sub-units that undergo hetero-dimerization and processing. Though inhibin-A and inhibin-B are considered the biologically active forms, the α-subunit can also be secreted in free form and can be recognized in some assays [7]. Consequently, detection of each of these forms in reproductively normal individuals or in disease states is complex, in part because antiserum used in assay development can lack specificity. Such is the case in studies conducted in horses. Most prior studies on the concentrations of inhibins in mares and stallions have utilized assays that were unable to distinguish between the different dimeric forms that can exist in the circulation for lack of specificity for one or other subunit [4,8–11].

Given the difficulty in measuring and monitoring intact inhibin-A and inhibin-B, and in the absence of purified equine inhibin of any type, it has only been possible to speculate on which form is likely more relevant in the horse physiologically or as a marker of disease. Assays capable of detecting and distinguishing inhibin-A and inhibin-B specifically might prove useful in better understanding ovarian physiology of mares and prove useful in equine reproductive diagnostics. Therefore, studies were conducted to investigate whether or not assays with apparent specificity for inhibin-A and inhibin-B could detect these isoforms in the mare. Patterns of secretion were examined in cyclic mares to determine which isoform might predominate and how concentrations change. Inhibin-A and inhibin-B concentrations were also investigated in samples from mares before and after hemi-ovariectomy which was conducted as part of an on-going study into effects of surgically halving follicle reserve on ovarian hormone secretion. These mares underwent a second surgery subsequently to remove the remaining ovary providing a baseline for ovariectomized mares. Inhibin-A and —B concentrations were also investigated in pregnant mares throughout gestation. Collectively, these data established normal concentrations in multiple reproductive states. Lastly, the utility of existing immuno-assays for inhibins for the diagnosis of GCTs in mares has been confirmed multiple times [6], but the relative value of measuring inhibin-A and inhibin-B specifically in blood has not been explored.

Herein we report the results of studies in mares re-examining changes in concentrations of inhibins using assays developed to detect inhibin-A, inhibin-B and “total” inhibins. The current studies included observations on changes in inhibin-A and —B in cyclic mares (Experiment 1), in young and old mares following hemi-ovariectomy (Experiment 2), during gestation in pregnant mares (Experiment 3) and in sera from mares with confirmed GCTs submitted for diagnostic testing to the Clinical Endocrinology Laboratory at the University of California, School of Veterinary Medicine, Davis, CA. The results provide confidence in the relative diagnostic value of these new assays, and offer new insight into the patterns of secretion under different physiological conditions in mares.

2. Materials & methods

3.1 Animals: Procedures were approved by the University of California, Davis Institutional Animal Care and Use Committee and by the Brazilian National Committee of Control in Animal Experimentation – CONCEA at the São Paulo State University (CEUA protocol 27/2016).

2.2. Western immunoblot analysis

Immunoblot analysis was performed using the mouse monoclonal antibodies 18/16A, 20/32C and 12/9A (Al006, Al007 and Al005, respectively, Ansh Labs, USA). The 18/16A antibody is specific to inhibin B subunit, 20/32C antibody is specific to inhibin α-subunit and 12/9A antibody is specific to activin B and inhibin βB subunit. Recombinant inhibin-A and —B were generated from CHO cells stably transfected with plasmid vectors engineered to express the cDNA encoding the human inhibin-α subunit in tandem (as a bicistronic construct) with cDNAs encoding the human inhibin-βA or —βB subunits, essentially as described previously [14]. Recombinant human inhibin-A and —B secreted from these cells were purified by affinity chromatography using a CNBr-coupled monoclonal antibody (44/53A, Ansh Labs, USA) recognizing the inhibin α subunit. So generated, recombinant inhibin-A (Al035, Ansh Labs, USA), inhibin-B (B0I43, Ansh Labs, USA), in addition to activin-B (659-AB, R & D System, USA), were separated using 10% polyacrylamide gel electrophoresis under non-reducing and reducing conditions. Proteins were transferred to nitrocellulose membranes and incubated with the above antibodies at 1:10,000 dilution, followed by a secondary horseradish peroxidase-conjugated goat anti-mouse IgG antibody (AP503P, Millipore, USA) at 1:5000 dilution. Proteins were visualized with the ECL plus Western blotting
2.3. Inhibin enzyme-linked immuno-sorbent assay (ELISA) assays

2.3.1. Inhibin ELISA design

The inhibin-A, inhibin-B and total inhibin assays were quantitative, sandwich-type immunoassays, using monoclonal antibodies generated in female Balb/c mice against α-, βA- and βB-subunits of mature inhibin as per the procedure reported elsewhere [15].

2.3.2. Inhibin-A ELISA

Inhibin-A concentrations were determined using Equine/Canine/Rodent Inhibin A ELISA reagents (AL-161, Ansh Labs LLC, Webster, TX). The assay used monoclonal antibodies specific to inhibitin βA subunit as capture (AI006, Ansh Labs LLC) and inhibitin α-subunit for detection (AI043, Ansh Labs LLC). The assay was calibrated to recombinant human inhibin A (AI035, 6.0–650 pg/mL) and was traceable to inhibin A Human WHO Reference Reagent 91/624 Version 3.0. In the first step 50 μL calibrators, controls, unknown samples and 25 μL each of inhibitin A assay buffer A and assay buffer B (ASB-123A and ASB 123B, Ansh Labs LLC) were added to inhibitin βA subunit antibody coated microtiter wells (1 μg/well) and incubated for 2 h. After the first incubation and washing, the wells were incubated with 100 μL biotinylated inhibitin α-subunit antibody (1/10,000 dilution) for 2 h. After the second incubation and washing, the wells were incubated with 100 μL streptavidin horseradish peroxidase conjugate (SHRP, 1/30,000 dilution) for 30 mins. After the third incubation and washing step, the wells were incubated with 100 μL substrate solution (TMB) for 10 mins.

2.3.3. Inhibin-B ELISA

Inhibin B concentrations were determined using Equine/Canine/Rodent Inhibin B ELISA reagents (AL-163, Ansh Labs LLC). The assay used monoclonal antibodies specific to inhibitin βB subunit as capture (AI005, Ansh Labs LLC) and inhibitin α-subunit as detection (AI043, Ansh Labs LLC). Recombinant human inhibitin B (BI043, 5.0–750 pg/mL) that was used as the calibrator was traceable to inhibitin B Human WHO Reference Reagent 96/784 Version 2.0. Briefly, 50 μL calibrators, controls, unknown samples and 50 μL each of inhibitin B assay buffer A and assay buffer B (ASB-207A and ASB-207B, Ansh Labs LLC) were added to inhibitin βB subunit antibody coated microtiter wells (1 μg/well) and incubated for 2 h. After the first incubation and washing, the wells were incubated with 100 μL biotinylated inhibitin α-subunit antibody (1/5000 dilution) for 1 h. After the second incubation and washing, the wells were incubated with 100 μL streptavidin horseradish peroxidase conjugate (SHRP, 1/20,000 dilution) for 30 mins. After the third incubation and washing step, the wells were incubated with 100 μL substrate solution (TMB) for 10 mins.

2.3.4. Total inhibin ELISA

Total inhibin concentrations were determined using animal Total Inhibin ELISA prototype assay reagents. The assay uses monoclonal antibodies specific to inhibitin α-subunit as capture (AI043, Ansh Labs LLC) and inhibitin α-subunit as detection (AI087, Ansh Labs LLC). The assay was calibrated to recombinant human inhibitin A (AI035, 6.0–500 pg/mL). Briefly, 50 μL calibrators, controls, unknown samples and 50 μL each of inhibitin B assay buffer A (ASB-123A, Ansh Labs LLC) was added to α-subunit sub-unit antibody coated microtiter wells (1 μg/well) and incubated for 2 h. After the first incubation and washing, the wells were incubated with 100 μL biotinylated inhibitin α-subunit antibody (1/2000 dilution) for 2 h. After the second incubation and washing, the wells were incubated with 100 μL streptavidin horseradish peroxidase conjugate (SHRP, 1/38,000 dilution) for 30 mins. After the third incubation and washing step, the wells were incubated with 100 μL substrate solution (TMB) for 10 mins.

2.3.5. Inhibin ELISA development

Reactions in all assays were stopped with addition of an acidic solution. The degree of enzymatic turnover of the substrate was determined by dual wavelength absorbance measured at 450 nm as the primary test filter and 630 nm as the reference filter. The absorbance measured was directly proportional to the concentration of recombinant inhibitin in the calibrators and did not show any cross-reaction to activin B, activin A, activin AB, inhibitin A, follistatin and myostatin at 1000 pg/mL. The percentage spiked recovery of recombinant human inhibitin A was 98–116% and for inhibitin-B was 89–103%. Potential interfering molecules (hemoglobin, triglycerides, bilirubin and biotin) when spiked at twice their physiological concentration in serum samples yielded inhibitin concentrations within 10–12% of the control levels. Linearity was verified in both follicular fluid and in serum. Sensitivities, intra- and inter-assay co-efficients of variation appear in Table 1.

2.4. Radio-immunooassays

2.4.1. Inhibins were determined by RIA essentially as previously described and validated [16,17].

Inhibin from bovine follicular fluid (bBNH-I-90/1; Robertson, Monash University, Clayton, Victoria, Australia) was used for iodination, and standards were derived from dilutions of equine follicular fluid calibrated against bovine inhibitin protein, which ranged from 0.15 to 10 ng/mL. The primary antibody was raised in rabbits against 31-kDa bovine inhibitin 1As, #1989; Robertson, Monash University, Clayton, Victoria, Australia). Standards (100 μL), controls (200 μL), or serum samples (200 μL) were pipetted into tubes. Standards and control serum received 100 μL buffer (0.04 M sodium phosphate, pH 7.4; 0.01 M disodium EDTA; 0.9% sodium chloride; 0.1% BSA), and non-specific binding (NSB) tubes received 200 μL of buffer only. Standard tubes also received 100 μL gelding serum. Each tube then received 100 μL of antibody (1/2000 dilution) and 100 μL of tracer (20,000 cpm) and were incubated overnight at room temperature. On the second day of the assay, 1 mL of goat-anti-rabbit antibody (1/250 dilution) was added to each tube. After 1.5 h of incubation at room temperature, tubes were centrifuged at 3210 × g for 30 min at 10 °C. Supernatants were aspirated and the radioactive pellets counted by a gamma counter. The standard curve ranged from 0.15 to 10 ng/mL, the sensitivity of the assay was 0.06 ng/mL and the intra- and inter-assay coefficients of variation were 7.1% (n = 6) and 6.0% (n = 6), respectively.

2.4.2. Follicle stimulating hormone (FSH)

Concentrations of FSH were determined using a previously validated RIA [16], with slight modifications. Highly purified detection system (Amersham Biosciences).

Table 1  Sensitivities, and intra- and inter-assay co-efficients of variation (from n = 36 determinations at each of two different concentrations) for inhibitin-A, inhibitin-B and total inhibitin ELISAs.

<table>
<thead>
<tr>
<th>Detected analyte</th>
<th>Assay sensitivity</th>
<th>Co-efficients of variation (n = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Intra-assay</td>
</tr>
<tr>
<td>Inhibitin-A (74 pg/ml)</td>
<td>2.3 pg/ml</td>
<td>3.2%</td>
</tr>
<tr>
<td>Inhibitin-A (204 pg/ml)</td>
<td>8.5%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Inhibitin-B (67 pg/ml)</td>
<td>2.3 pg/ml</td>
<td>4.6%</td>
</tr>
<tr>
<td>Inhibitin-B (203 pg/ml)</td>
<td>6.3%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Total inhibitin (70 pg/ml)</td>
<td>6.4 pg/ml</td>
<td>5.8%</td>
</tr>
<tr>
<td>Total inhibitin (247 pg/ml)</td>
<td>5.6%</td>
<td>3.5%</td>
</tr>
</tbody>
</table>
pituitary derived equine FSH (e265B, Papkoff, UC Davis, CA) was used for standards (ranging from 0.25 to 64 ng/mL) and for iodination. The primary antibody was LSU 3D-2 anti-oFSH from Dr. D.L. Thompson, LSU, Baton Rouge LA, used at a 1:20,000 dilution. One hundred µL of standard, control, or serum were added to tubes along with 150 µL antibody (except to total counts and NSB tubes), and incubated overnight at room temperature. On day 2, tracer (20,000 cpm/50 µL) was added to all tubes, and tubes were incubated for 3 days at 4°C. On the fifth day, 100 µL of a 1.0% normal rabbit serum (Sigma –7523) and 1 mL of a 1:100 dilution of goat anti-rabbit antibody (Equitech-Bio GARG-500) in 5% polyethylene glycol were added to each tube. After incubation for 2 h at room temperature, tubes were centrifuged at 1430 × g at 10°C for 20 min. Supernatants were poured off and the pellets counted in a gamma counter. The sensitivity of the assay was 0.5 ng/mL. and the intra- and inter-assay coefficients of variation were 6.25 (n = 6) and 6.5% (n = 3), respectively.

2.5. Anti-Müllerian hormone (AMH)

AMH concentrations were determined using Equine AMH ELISA reagents (AL-115, Ansh Labs LLC) essentially as recommended by the manufacturer. The AMH ELISA is a quantitative 3 step sandwich type immunoassay. In the first step 50 µL of calibrators, controls, unknown samples and 50 µL of assay buffer (ASSB-113) were added to antibody coated microtiter wells and incubated for 2 h at 600 rpm on a plate shaker. After the first incubation and washing, the wells were incubated with 100 µL of a second, biotinylated AMH antibody (BCR-115) for 1 h on a plate shaker. After the second incubation and washing, the wells were incubated with 100 µL streptavidin horseradish peroxidase conjugate (SAR-115) for 30 mins on a plate shaker. After the third incubation and washing step, the wells were incubated with 100 µL TMB chromagen solution (TMB-100) and shaken for 8 mins. The reaction was stopped with addition of 0.2 M sulfuric acid (stopping solution). Substrate turnover was determined by dual wavelength absorbance at 450 nm (primary test filter) and 630 nm (reference filter) on a Molecular Devices VersaMax ELISA plate reader (Sunnyvale, CA, USA). The standard curve ranged from 0.063 to 15.3 ng/mL, the intra- and inter-assay co-efficients of variation were 2.1 (n = 6) and 6.2% (n = 6), respectively, and the sensitivity of the assay was 0.05 pg/mL.

2.6. Data analysis

Statistical analysis utilized Mixed Model procedures (SAS, Raleigh NC). Main effects of time (Expt 1) and time and age (Expt 2) were included in repeated measures analyses. Both linear and quadratic effects were considered. A significant difference was determined by orthogonal contrasts. Pearson’s correlation co-efficients were estimated amongst hormones in each experiment using the Proc Corr procedure. The pregnancy data was examined for linearity using Regression Model procedures in SAS and comparisons between inhibins during pregnancy were made using Mixed Model procedures and orthogonal contrasts. Differences in detection of confirmed GCTs among inhibin-A, inhibin-B and the inhibin RIAs were evaluated by Chi-square analysis and Pearson’s correlation co-efficients were estimated using Proc Corr. Data were log transformed for normality when necessary.

3. Results

Supernatant from cells expressing inhibin-A investigated using monoclonal antibody specific for the inhibin βA subunit (#A1006, Fig. 1A) detected a single band between 10 and 15 kDa under reducing conditions with a faint band at 50 kDa. Under non-reducing conditions, a major band was recognized slightly above 25 kDa as well as a faint band at 50 kDa and another between 20 and 25 kDa. The monoclonal antibody specific for the inhibin α subunit (#A1007, Fig. 1B) detected a single band between 15 and 20 kDa under reducing conditions and a single band slightly above 25 kDa under non-reducing conditions. The βB monoclonal antibody (#A1005, Fig. 1C) detected a major band between 10 and 15 kDa and minor band around 50 kDa under reducing conditions. Under non-reducing conditions there was a major band detected at slightly above 25 kDa and multiple minor bands, one at around 50 kDa and another between 20 and 25 kDa. The activin-B positive control was detected as a single band between 10 and 15 kDa under reducing conditions and a single band at slightly above 25 kDa under non-reducing conditions.

Changes in concentrations of inhibin-A, inhibin-B and total inhibin were monitored in mares during the estrous cycle with assays developed using these monoclonal antibodies. Of the 6 mares monitored for cyclic activity, 4 had an average inter-ovulatory interval of 26 ± 1 days. There was a highly significant quadratic effect of time (days between ovolutions) on inhibin-A concentrations (P < 0.0001) in these 4 mares. On average, inhibin-A concentrations dropped 8-fold from a peak of 80.3 ± 28.7 pg/mL around the time of ovolution to a nadir of less than 10 pg/mL on day 12 of the cycle (P < 0.05), increasing again to 91.4 ± 16.9 pg/mL on day 19 (P < 0.01) in association with the next ovulation (Fig. 2). Although a similar pattern was seen for inhibin-B, and concentrations of inhibin-A and –B were highly correlated (r = 0.79, P < 0.001), the magnitude of change from ovulation to mid-cycle (46.2 ± 20.7 and 15.1 ± 4.1 pg/mL, respectively, Fig. 2) were not as great or statistically significant and there was no main effect of time (P > 0.1). However, there was a significant main effect of time on the ratio on inhibin-A to inhibin-B (A/B; P < 0.0001: Fig. 3). The ratio of A/B dropped significantly from day 0 to day 11 (P < 0.05) and was significantly less than 1 on days 10 and 13 (P < 0.01; Fig. 3). Total inhibin concentrations also decreased from a peak around ovulation, but the variation among mares was extreme and there was no discernible increase associated with the subsequent ovulation (data not shown). Correspondingly, the cyclic changes in inhibin-A and inhibin-B were less correlated with total inhibins (r = +0.41 with inhibin-A and r = +0.61 with inhibin-B, P < 0.0001). The remaining 2 (of the 6) mares monitored had grossly extended inter-ovulatory intervals of 40 and 45 days and their data were analyzed separately. Both experienced multiple peaks in both inhibin-A and inhibin-B concentrations during the interval between ovolutions (Fig. 4). These peaks of inhibin-A and inhibin-B appeared interspersed between peaks of FSH (Fig. 4) and, as with the mares with more normal cycle lengths, this was supported by a negative correlations between FSH and both the inhibin-A (r = −0.49 and −0.31, P < 0.05) and inhibin-B (r = −0.49 and −0.29, P < 0.05) for the mares with the 40 and 45 day cycles, respectively. There were no age-related differences (P > 0.1) in concentrations of either inhibin-A (66.0 ± 26.0 vs 45.8 ± 10.1 pg/mL, young and old mares, respectively) or inhibin-B (27.9 ± 6.0 vs 28.2 ± 6.2 pg/mL, young and old mares, respectively) before surgery in Experiment 2 (Fig. 5). Similarly, there was no overall main effect of time or age on either inhibin-A or -B. However, hemi-ovariectomy affected inhibin-A and inhibin-B concentrations in young mares acutely. In these mares, inhibin-A decreased by one third to 44.0 ± 18.9 pg/mL on the day after surgery (P < 0.05) and to a nadir of 32.6 ± 6 pg/mL on day 4. Inhibin-B also declined in young mares by 50% following hemi-ovariectomy to 14.3 ± 2.3 pg/mL one day later (P < 0.05), after which it slowly returned to pre-surgical
Western immunoblots of supernatant from cultured CHO cells secreting recombinant human inhibin-A (panel A & B) and inhibin-B (panel C). Supernatants were run under both reducing (R) and non-reducing (NR) conditions. Shown are results from experiments detecting: A. Inhibin-A (NR, 18.4 ng/lane) and the βA sub-unit (R, βA) using inhibin βA specific 18/16A (AI006) monoclonal antibody. B. Inhibin-A (R, Inh-A) and the α subunit (Inh-α) using inhibin-α sub-unit specific (AI007) monoclonal antibody (Inh-A mAB). C. Inhibin-B (Inh-B, 62.5 ng/lane) and activin-B (Act-B, 25 ng/lane; R&D Systems) using inhibin βB specific 12/9A (AI005) monoclonal antibody. Detected bands include pro-βB subunit (50-54kD) of inhibin-B (R and NR, Inh-B), dimeric βB (NR, Inh-B; NR, Act-B, 28kD) and monomeric βB (R, Inh-B and Act-B, 14kD) fragments.

Daily concentrations (pg/mL) of inhibin-A (solid line) and inhibin-B (dashed line) in serum from cyclic mares (n = 4) with a mean inter-ovulatory interval of 26 ± 1 days. Differences in concentrations of inhibin-A between day 0 and 12 (P < 0.05), and between day 12 and 19 of the cycle are as indicated (P < 0.01). Shown are means ± standard errors of the mean.

Ratio of the concentrations of inhibin-A and inhibin-B (A/B) in serum from cyclic mares (n = 4) with a mean inter-ovulatory interval of 26 ± 1 days. There was a significant main effect of day (P < 0.0001), the ratio on day 11 was lower (P < 0.05) than day 0 and the ratios on day 10 and day 13 were significantly less than 1 (inhibin-B was higher than inhibin-A on these days; P < 0.01).
levels by day 10 (Fig. 5). In contrast to young mares, there was no
decrease in inhibin-A or -B or concentrations after surgery in the
older mares. Though few of the mares were cycling at the time of
the second surgery, removal of the remaining ovary decreased
inhibin-A from 10.7 ± 3.9 to 2.4 ± 0.3 pg/ml, and inhibin-B from
13.5 ± 3.5 to 6.2 ± 1.4 pg/ml.

Concentrations of inhibin-A and inhibin-B both decreased
significantly during gestation (P < 0.0001). The decline in inhibin-A
concentrations was most dramatic between GD30 and GD60 (Fig. 6,
P < 0.0001) and maintained a steady low baseline for the remainder
of pregnancy. Inhibin-B concentrations declined more gradually to
a nadir around GD200 (P < 0.05). Though inhibin-A concentrations
were higher on day 0 and day 30 of gestation, and concentrations of
both isoforms were generally very low, inhibin-B concentrations
exceeded those of inhibin-A from gestation day 60 until term
(Fig. 6, P < 0.0001).

The standards used in the inhibin RIA, when assayed for inhibin-A
and inhibin-B, detected on average 9.5- and 19.1-fold less,
respectively, than was detected by the polyclonal antisera in the
RIA, based on the slopes of the regression curves generated
(R² > 0.99, not shown). In the samples submitted for a suspected
GCT, and therefore assayed for inhibin using the RIA, there was a
strong positive linear correlation between the estimates from the
RIA and the immuno-assays for inhibin-A (r = +0.74, P < 0.001) and
inhibin-B (r = +0.68, P < 0.001). However, there was no significant
correlation between AMH and the either inhibin-A or inhibin-B
concentrations (P > 0.3). The diagnostic potential for using
inhibin-A and/or inhibin-B in suspected cases of GCTs was evaluated
using the mean ± 3 standard deviations calculated on the data
from mares in experiments 1 and 2 as reference ranges. So calcu-
lated, the upper limit of normal was 160 pg/ml for Inhibin-A and
100 pg/ml for inhibin-B. With these diagnostic criteria, inhibin-B
detected 26/34 (76%) of confirmed cases of GCTs compared with
24/34 (71%) detected using the clinical inhibin RIA and 10/34 (29%)
for inhibin-A. The inhibin-B assay was comparable to the inhibin
RIA in detecting GCTs (P > 0.5) and both were significantly better
than was inhibin-A (P < 0.001).

4. Discussion

To the best of the authors’ knowledge, this is the first study
reporting serum concentrations of inhibin-A and inhibin-B in ma-
res. Results reported provide biochemical and biological validation

---

**Fig. 4.** Daily concentrations of inhibin-A (solid line, triangles, pg/mL), inhibin-B (dashed line, squares, pg/mL) and FSH (dotted line, open circles, ng/mL ± 5) in serum from 2 mares with grossly extended inter-ovulatory intervals of 40 and 45 days.

**Fig. 5.** Daily serum concentrations (pg/mL) of inhibin-A (upper panel) and inhibin-B (lower panel) in young (n = 6, 6 ± 1 year of age, solid line) and older (n = 6, 19 ± 1 year of age, dashed line) mares before (day 0) and after hemi-ovariectomy (days 1–15). Shown are means ± standards errors of the mean. † Indicates difference between pre-surgical (day 0) and post-surgical (day 1) concentrations in young mares only, P < 0.05.

**Fig. 6.** Concentrations (pg/ml) of inhibin-A (solid) and inhibin-B (dashed) in plasma of mares (n = 5) bled throughout gestation. †Difference between GD30 and 60 for inhibin-A, P < 0.0001. ‡Difference between GD0 and 200 for inhibin-B, P < 0.05.
for immuno-assays using monoclonal antibodies specifically detecting inhibin A, B and α-subunits, and thereby inhibin-A and inhibin-B in sera from cyclic (n = 6) and hemi-ovariectomized mares (n = 12), pregnant mares (n = 5), as well as mares with confirmed GCTs (n = 44). Inhibin concentrations in cyclic mares were first measured using a RIA with polyclonal antiserum raised against a peptide fragment of the porcine inhibin α-subunit that was also used for preparation of the tracer [8]. Consequently, the assay did not distinguish free α-sub-unit from dimeric forms. Inhibin concentrations did not vary dramatically through the cycle, a peak at ovulation was not obvious for instance, but inhibin was negatively correlated with FSH [8]. Several other investigators employed assays developed using purified bovine inhibin as the antigen for raising antisera, labeling tracer and standards [4,9–11,18]. These assays also lack isoform or sub-unit specificity and results were reported as inhibins. For instance, peak inhibins concentrations at ovulation were reported to average > 540 pg/mL, declining by 50% to mid-luteal phase concentrations of around 210 pg/mL and were also negatively correlated with FSH [4]. Some have suggested this may be associated with uptake of inhibin by follicular fluid released into the peritoneal cavity at ovulation [10]. In any case, similar findings by others confirmed these circulatory patterns [9,11]. The current data are generally consistent with those reported previously but extend them, providing evidence that inhibin-A concentrations are higher than inhibin-B they peak at ovulation. Both then decrease during the mid-luteal phase and at their nadir inhibin-B concentrations predominate over inhibin-A. However, more dynamic fluctuations in concentrations were detected in this study than previously (> 8-fold nadir to peak for inhibin-A, > 3-fold for inhibin-B), perhaps because the assays employed are more isoform specific. The mares in this study did exhibit long inter-ovulatory intervals. Those with an interval of 26 days were at the very extreme of that considered normal for mixed breed light horses [19] though these mares were normal by all clinical measures. Observations were insufficient to determine if cycle length in these mares was associated with diestrous ovulations [20]. This seems unlikely in view of the fact that there were no inter-ovulatory increases in inhibin-A or inhibin-B concentrations detected in those mares, but may well have been the case for the other 2 mares with 40 and 45 day inter-ovulatory intervals. Regardless of whether or not the cyclic changes observed in the majority of mares studied here are representative of what could be regarded as “normal” cycles, inhibin-A exhibited ovulation-related peaks and a nadir at mid-cycle that were distinct from, but still highly correlated with, inhibin-B.

As noted above, few studies have been conducted to investigate differences that might exist in circulating concentrations of dimeric inhibin-A and inhibin-B in horses, due to a lack of reagents with sufficient sub-unit specificity for the equine hormones. To date, expression of the inhibin-βB sub-unit in equine ovaries has been investigated by immuno-histochemistry but available data are somewhat contradictory. The inhibin βB sub-unit was not detectable in any of 4 GCTs in one study [21] but was reportedly expressed along with the α-sub-unit and the βA sub-unit in both theca and granulosa of equine follicles by others [9]. Inhibin-A and inhibin-B were detected in equine follicular fluid, along with other growth factors, using specific ELISAs but systemic concentrations were not reported [22]. Follicular fluid concentrations of inhibin-A were observed to increase earlier in follicular development (around the time of deviation) than did inhibin-B which is consistent with the increasing concentration of inhibin-A and increasing ratios of A/B around ovulation. This suggests a level of differential regulation of the inhibin-A and -B dimeric forms and possibly different physiological roles. It would appear that dominant follicles secrete more inhibin-A than inhibin-B. Inhibin-B concentrations were also detected in systemic blood from 4 mares with GCTs in a prior study [23] using a sandwich ELISA for that isoform but inhibin-A concentrations were not investigated or not reported. Three of these mares were re-examined after surgical removal of the tumor, all of which exhibited a (variable) decline. In any case, we believe the current data are the first relating to circulating inhibin-B concentrations in cyclic mares. The lack of correlated changes in total inhibins may explain why previous, less specific assays did not detect such marked cyclic patterns as those reported here and is consistent with greater specificity shown in the current assays developed for inhibin-A and -B.

A significant decline in inhibin-A and inhibin-B was also observed one day after hemi-ovariectomy in young mares, providing additional biological validation for these assays in terms of supporting an ovarian source. Inhibin-A and -B concentrations rebounded thereafter consistent with a rapid compensatory ovarian hypertrophy response, likely associated with a re-establishment of follicle numbers and/or size. However, the postsurgical decrease was observed only in young (6 year old) mares, not in older (19 year old) mares. In young mares, both inhibin-A and inhibin-B concentrations recovered, though the time courses were somewhat different. A more rapid decline and recovery of inhibin-B than inhibin-A in the young hemi-ovariectomized mares could reflect differences in half-life as it might otherwise reflect differential regulation and rates of recovery of follicle populations of different sizes. The lack of specific assays in the past has not allowed the half-life of inhibin-A and inhibin-B to be assessed and compared in horses but such studies are now possible. Analysis of appropriately timed longitudinal samples taken following complete gonadectomy will be required to properly address that issue [1].

The reasons for the lack of change in inhibin-A and -B concentrations following hemi-ovariectomy in older mares are unclear at this time, but it suggests the possibility that inhibins are secreted by tissues in mares other than the ovaries. Using the Monash reagents and the clinical assay, as reported here, inhibin secretion by adrenal cortical tumors, as well as cases of adrenocortical hyperplasia, was detected in neutered dogs [24]. This is consistent with reports showing inhibin sub-unit expression and inhibin secretion by adrenal tissues of other species including humans [25]. These data would seem to provide a rationale for further studies investigating the secretion of inhibins by adrenal or perhaps other extra-gonadal tissues in horses, and how this might influence cyclicity and fertility, especially in aging mares. Additionally, inhibin-A and -B concentrations in the 2 mares with extended inter-ovulatory intervals provided evidence that follicle waves may be monitored in systemic blood by inhibin concentrations in this species. This also appears to be a novel and potentially significant finding which is currently being further investigated with more careful, frequent and detailed clinical observation. While AMH is considered a useful biomarker for ovarian reserve [26–28], it is not subject to pituitary feedback and secretion is limited to the peri-antral stages of follicular growth when gonadotrophic responsiveness develops [26]. In this regard, inhibin-A or inhibin-B may prove to be more valuable biomarkers of the potential for ovarian response to gonadotrophic stimulation, if not in mares then perhaps in other species. In any case, the differences in response to hemi-ovariectomy in the younger compared with the older mares suggests that inhibin-A and inhibin-B may also provide some insight into ovarian aging and the associated decline in fertility in this species. Given the more dynamic changes in inhibin-A concentrations during the equine estrous cycle, the decline that follows hemi-ovariectomy and the higher negative correlation with concentrations of FSH, inhibin-A may be more significant as a biomarker or physiological regulator of the ovarian-pituitary axis in the horse.
Inhibin-A and inhibin-B concentrations decreased generally during gestation in mares and, as with fluctuations seen during cyclicity, inhibin-A decreased far more than did inhibin-B. The more marked decline in inhibin-A concentrations than inhibin-B reversed the ratio of A/B seen at ovulation (day 0) and at 30 days of gestation so that, although still extremely low, inhibin-B concentrations were significantly higher than inhibin-A at GD 60 and remained so for the rest of pregnancy. These data contrast those reported previously in pregnant mares [29] where an increase in immuno-reactivity was seen during gestation coinciding with the growth of the fetal gonads. Inhibin concentrations in that study were measured using an immuno-assay that did not discriminate different possible forms of the hormone and might have included free α-sub-unit. The source (fetal or maternal) was unclear, but the hormone detected was biologically inert [29]. The reason for the discrepancy between studies is unknown but it could relate once again to the greater specificity of the assays utilized here. In any case, the eventual dominance of inhibin-B concentrations over inhibin-A observed here was somewhat similar to that seen mid-cycle in the non-pregnant mares. If the origin of inhibin-A and inhibin-B in pregnant mares is the maternal ovaries, then secretion would likely reflect follicle populations and changes in them with advancing gestation. Though occurring far earlier in gestation, if the origin of inhibin-A and -B detected here still reflects secretion by the maternal ovaries, it is consistent with the disappearance of ovarian follicles and follicular activity seen in pregnant mares with advancing gestation as originally observed [30].

In contrast to the clear evidence for secretion of both inhibin-A and -B by the ovary during cyclicity and early pregnancy, the current results indicate that equine GCTs secrete predominantly inhibin-B. Previous studies reported finding the inhibin-α sub-unit and βA expression in GCTs [21,31,32] as well as in equine follicular fluid [33]. This is consistent with the significant positive correlation between inhibin-A and inhibin-B concentrations in mares with confirmed GCTs examined here. The current data indicate quite clearly however that the secretion of inhibin-B is a far better biomarker for equine GCTs than is inhibin-A. Moreover, the secretion on inhibin-B by equine GCTs is consistent with prior reports [9,23] as noted above. In contrast to findings previously reported from our laboratory [34], there was no correlation between inhibins determined by the clinical assay, or inhibin-A or -B, and concentrations of AMH in the present case series, though inhibins and AMH are both granulosa cell products [35]. This is perhaps not surprising given the likelihood that the peak of secretion of each of these hormones occurs at different stages of follicular development. Clearly, inhibin-A and inhibin-B secretion is periodic and highly regulated in cyclic mares but there is little variation across cycles in concentrations of AMH [39], perhaps reflecting more stable population of peri-antral follicles. The lack of correlation in mares with GCTs in this series suggests these hormones provide different biological information with potentially additive value. It is of interest also that the results in mares with GCTs contrast those in women with granulosa cell tumors which do not appear to be so selective in the form of inhibins they secrete [3,15,36]. How this might relate to the differences in behavior of the tumors (in contrast to women, rarely malignant in mares even when large) or to the more common involvement of interstitial (theca-derived, androgen secreting) elements in equine GCTs [37] is unknown. Regardless, the immunobLOTS data and the differences in secretion of inhibin-A and inhibin-B detected in this equine case series both support the specificity of these assays for their isoform targets. Inhibin-B performed as well as the clinical assay currently used by the UC Davis Clinical Endocrinology Laboratory which recognizes multiple forms. Additional clinical data will be needed to better assess the true sensitivity of the detection of equine GCTs using this inhibin-B assay. In conclusion, the current data provide confidence in the ELISAs developed to detect inhibin-A and inhibitin-B with specificity in horses in a physiological and (in a clinical sense) a diagnostically useful range. Furthermore, evidence is provided suggesting that inhibin-A may be more likely to be physiologically relevant (greater fluctuations during the cycle, more negatively correlated with FSH and a more rapid and marked decline during gestation) than inhibin-B in mares, but that inhibitin-B is the isoform whose secretion is increased more reliably in mares with GCTs. This is of relevance for diagnosing GCTs, even in pregnant mares, but may also provide insight into the pathophysiology of this condition. Studies correlating changes in inhibin-A and inhibitin-B with well-characterized follicular waves in mares experiencing normal and extended cycles are in progress to confirm the origins of the apparent patterns observed.

Statement of potential conflict of interest

As a potential conflict of interest, the authors acknowledge that B. Kalra, G. V. Savjani and A. Kumar are employees of Ansh Labs LLC, Webster, TX, USA, 77598, the company that developed and markets the inhibin and anti-Mullerian hormone ELISA assay platforms used in the determinations reported here.

Acknowledgements

This research did not receive any specific grant funding from agencies in the public, commercial, or not-for-profit sectors. However, the authors acknowledge the generous support of the John P. Hughes Endowment Fund for providing partial support for these studies. The authors would also like to express their sincere gratitude to Drs. Jenny Boye and Catherine Renaudin for invaluable help in monitoring mares and collecting blood samples, and to Dr. Jan Roser who generously donated reagents used to assay FSH.

References

[14] Pangas SA, Woodruff TK. Production and purification of recombinant human...


